The mRNA ‘revolution’ continues..
NEW CLINICAL TRIALS
mRNA jabs are not going away any time soon.
In fact, it seems like traditional vaccines are the ones that are indeed being replaced.
The U.S. National Institutes of Health (NIH) is the latest institution to begin enrolling participants in a trial to test an experimental universal influenza vaccine using mRNA technology.
The latest move sees a Phase 1 trial at Duke University in North Carolina begin, testing the ‘safety and immune response’ of H1ssF-3928 mRNA-LNP, developed by the U.S. National Institute of Allergy and Infectious Diseases (NIAID).
The new trial combines the H1ssF nanoparticle vaccine with messenger RNA (mRNA) as the platform, with the end goal that it’ll ‘deliver a more efficient, targeted immune response’.
The NIH is looking for 50 volunteers ages 18 to 49 for the Phase 1 trial, where some 50 participants aged 18-49 will be split into three groups and given 10, 25 and 50 micrograms of the active biological product, respectively.
When ‘optimal dosage’ is then determined, another 10 participants will get this measured jab.
There will also be an additional group who will receive a current quadrivalent seasonal flu shot, so researchers have a comparative dataset that takes into account ‘the immune response and safety of readily available influenza vaccines’.
Participants in the trial will be followed for up to one year after vaccination to primarily ‘track its safety and efficacy’.
“A universal influenza vaccine would be a major public health achievement and could eliminate the need for both annual development of seasonal influenza vaccines, as well as the need for patients to get a flu shot each year,” said Dr Hugh Auchincloss, acting NIAID Director.
“Ssome strains of influenza virus have significant pandemic potential. A universal flu vaccine could serve as an important line of defence against the spread of a future flu pandemic.”
This trial comes after tan initial NIAID’s Vaccine Research Center study on the safety and immune response of the H1ssF (H1 hemagglutinin stabilized stem ferritin) nanoparticle vaccine.
The Phase 1 trial, from April 2019 to March 2020, delivered “broad antibody responses in the 52 participants aged 18-70”.
The results of the trial were published last month in the journal Science Translational Medicine.
NIAID are not alone in their endeavours, either.
There are several universal flu vaccines in various stages of development and testing.
The shots use the same mRNA technology that’s in the Covid-19 Pfizer and Moderna vaccines.
And we all know how that went..
Now, as predicted, it seems the future of all vaccines is heading towards this type of technique.
THE MRNA FUTURE
The H1ssF-3928 mRNA-LNP vaccine is not the only potential flu shot at this stage of development.
Last week, CureVac and GSK began a combined Phase 1/2 trial for their ‘multivalent, modified mRNA seasonal influenza vaccine’.
In addition, our good friends at Pfizer and BioNTech are leading the way, launching Phase 3 of their ‘quadrivalent nucleoside-modified messenger RNA (modRNA) vaccine’ last September, administering the drug to 25,000 adults in the US aged 18 and over.
Pfizer says their approach will ‘target four known flu strains recommended by the World Health Organization (WHO)’.
They’ve also begun Phase 1 trials of a flu shot combined with their COVID-19 Omicron BA.4/BA.5 vaccine.
Moderna is once again far behind, admitting last month its Phase 3 trial of its vaccine, mRNA-1010, “did not accrue sufficient cases at the interim efficacy analysis to declare early success.”
This follows on from 2021’s disappointing trial results.
Just like during COVID, the mad cash race is on to develop the first ‘safe and effective’ mRNA flu shots, with the aim for each and every vaccine to incorporate this method moving forward into the future.
We are even seeing pushes being made for mRNA vaccines to hit Australian livestock in the near future.
Australia is ready to welcome this shift with open arms, building a mRNA facility in Melbourne to produce the products, as well as plans by the QLD government for a major research hub in the Sunshine State.
‘Universal’ flu vaccines are likely to rolled out right here at home after ‘trials’ have finished, most likely included as part of CSL’s $313 million deal to bring ‘next-generation’ mRNA jabs to our shores.
Yes, the same CSL that knowingly released millions of contaminated polio vaccines into Australian society.
Money talks, but as we have exposed with our Pfizer Papers series by Dr. T.J. Coles, many shortcuts and deceptions are taken to ensure these ‘trials’ end up ‘passing’ all of the hurdles they need to go through.
This includes mass censorship of the safety standards and procedures undertaken when developing the jabs themselves.
It also includes tactics like exploiting controversial clinical trial methods where data can be manipulated, injury statistics can be rounded to zero, and deaths can be covered up, all to ensure the “biological product” makes it into the arms of billions.
Of course, vaccines are only the tip of deception from Big Pharma.
But it seems mRNA jabs, and the long-term side effects that will need to be treated from them, are the new billion dollar investments on the block that everyone is trying to get a slice of.
All at the expense of the true meaning of healthcare, to cure, not create lifelong consumers.
When will the madness end?
Will people really line up for these ‘universal’ vaccines once they are released?
Will we see more flu season propaganda as these jabs are set to hit shelves?
For more TOTT News:
Facebook — Facebook.com/TOTTNews
YouTube — YouTube.com/TOTTNews
Instagram — Instagram.com/TOTTNews
Twitter — Twitter.com/EthanTOTT
Bitchute — Bitchute.com/TOTTNews
Gab — Gab.com/TOTTNews